Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BCD-201 vs Keytruda in Advanced Malignancies
NCT05739006Phase 1Unknown
- Sponsor
- BIOCAD
- Start
- Feb 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BCD-201 in melanoma and non-small cell lung cancer (NSCLC) (2 arms), sponsored by BIOCAD. Primary endpoint: Area Under the Concentration-Time Curve from Time 0 to 504 Hours. Status: unknown.
02
Drugs
BCD-201
03
Conditions
melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05739006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05739006.